295
Participants
Start Date
February 16, 2021
Primary Completion Date
August 13, 2024
Study Completion Date
August 28, 2024
KAF156
Provided as 50 mg or 100 mg tablets, to be taken QD 2 or 3 Days in combination with LUM-SDF, dose is based on body weight
LUM-SDF
Provided as 60 mg, 120 mg or 240 mg powder in sachet, to be taken QD 2 or 3 Days in combination with KAF156, dose is based on body weight
Coartem
Coartem® (dispersible tablets in blister pack) (for Cohorts 1 and 2), dose is based on body weight
Novartis Investigative Site, Banfora
Novartis Investigative Site, Ouagadougou
Novartis Investigative Site, Commune de La Kenya Lubumbashi
Novartis Investigative Site, Kati
Novartis Investigative Site, Sotouba
Novartis Investigative Site, Bobo-Dioulasso
Novartis Investigative Site, Sabou
Novartis Investigative Site, Abidjan
Novartis Investigative Site, Lambaréné
Lead Sponsor
European and Developing Countries Clinical Trials Partnership (EDCTP)
OTHER_GOV
Novartis Pharmaceuticals
INDUSTRY